[Comment] Expression of concern—Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study

Related Posts

• Phase 2 RACE IT Study: Revolutionizing Treatment for Urothelial Carcinoma Patients

  KEY TAKEAWAYS The RACE IT trial is a prospective, single-arm, multicenter, phase II trial. The…

• Recent Outcomes of Phase 1 Study of Elranatamab for R/R MM Patients

  KEY TAKEAWAYS Elranatamab is a bispecific molecule that targets B-cell maturation antigen (BCMA) on multiple…

• Phase 2 RACE IT Study: Revolutionizing Treatment for Urothelial Carcinoma Patients

  KEY TAKEAWAYS The RACE IT trial is a prospective, single-arm, multicenter, phase II trial. The…

• Phase 2 RACE IT Study: Revolutionizing Treatment for Urothelial Carcinoma Patients

  KEY TAKEAWAYS The RACE IT trial is a prospective, single-arm, multicenter, phase II trial. The…

• Phase 2 RACE IT Study: Revolutionizing Treatment for Urothelial Carcinoma Patients

  KEY TAKEAWAYS The RACE IT trial is a prospective, single-arm, multicenter, phase II trial. The…

• Phase 2 RACE IT Study: Revolutionizing Treatment for Urothelial Carcinoma Patients

  KEY TAKEAWAYS The RACE IT trial is a prospective, single-arm, multicenter, phase II trial. The…